We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+14.54%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.47B
AUM Growth
-$118M
Cap. Flow
-$497M
Cap. Flow %
-20.15%
Top 10 Hldgs %
35.06%
Holding
147
New
13
Increased
26
Reduced
28
Closed
38

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$70.1M
2
ADPT
Adeptus Health Inc
ADPT
+$48.6M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$22.8M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$17.2M
5
XNPT
XENOPORT, INC.
XNPT
+$15.9M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$41.3M
2
NXTM
NxStage Medical Inc.
NXTM
+$32.2M
3
ELGX
Endologix Inc
ELGX
+$28.8M
4
GSK icon
GSK
GSK
+$24.8M
5
LOXO
Loxo Oncology, Inc
LOXO
+$22.5M

Sector Composition

Rank Sector Weight
1 Healthcare 68.33%
2 Financials 4.33%
3 Technology 0.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MZOR
126
DELISTED
Mazor Robotics Ltd.
MZOR
– –
-228,909
Closed -$2.52M
KND
127
DELISTED
Kindred Healthcare
KND
– –
-72,100
Closed -$1.14M
ELOS
128
DELISTED
Syneron Medical Ltd
ELOS
– –
-2,079,013
Closed -$14.9M
WINT
129
DELISTED
Windtree Therapeutics Inc
WINT
– –
-609,857
Closed -$2.56M
ZLTQ
130
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-420,063
Closed -$13.5M
BITI
131
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-219,558
Closed -$2.87M
BEAT
132
DELISTED
BioTelemetry, Inc.
BEAT
– –
-222,215
Closed -$2.72M
BDSI
133
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-700,000
Closed -$3.89M
DSCI
134
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-1,002,201
Closed -$4.72M
LJPC
135
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-65,000
Closed -$1.81M
2 3 4 5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2015 Portfolio in Review

As of Q4 2015, Deerfield Management held 147 positions worth $2.47B, down 4.6% from $2.59B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $497M in Q4 2015, closing 38 positions and reducing 28 holdings. Its most notable exit was bluebird bio, an estimated $41.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Five Prime Therapeutics, Inc. worth $28.2M.

  • Deerfield Management's largest Q4 2015 buy was Five Prime Therapeutics, Inc.: 680,000 shares worth $28.2M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $70.1M increase.
  • Deerfield Management's biggest Q4 2015 reduction was NxStage Medical Inc., cutting an estimated $32.2M.
  • Deerfield Management fully exited bluebird bio in Q4 2015, selling an estimated $41.3M.
  • Deerfield Management's ten largest holdings make up 35% of its $2.47B portfolio in Q4 2015.
  • Deerfield Management opened 13 new positions and closed 38 in Q4 2015.
  • Deerfield Management's portfolio value fell 4.6% quarter-over-quarter to $2.47B.

Based on Deerfield Management's 13F filing for Q4 2015, filed 16 Feb 2016.